Clinical Trials Logo

Warts clinical trials

View clinical trials related to Warts.

Filter by:

NCT ID: NCT05409365 Recruiting - Healthy Clinical Trials

Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris

Start date: May 1, 2022
Phase:
Study type: Observational

This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.

NCT ID: NCT05314127 Recruiting - Warts Flat Clinical Trials

Efficacy of Tazarotene in Treatment of Verruca Plana

Start date: April 15, 2022
Phase: Phase 2
Study type: Interventional

Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment for warts. Verruca plana is not merely an infectious disease but also affects the quality of patients' life. Verruca plana causes major cosmetic and social concerns. Lesions' persistence and recurrence cause frustrations and psychological distress which motivate patients to seek different treatment strategies. Verruca plana commonly affects the school aged children which augments its effect on the psychological and social development of children with stigmatization and bullying are great risks. The available treatment strategies neither ensured complete clearance of the disease nor were free of side effects. Frequently used physical removal methods are operator dependent and commonly lead to irritation, local inflammation, scars, dyspigmentation, and disfigurement. In this study we evaluate the efficacy and the safety of tazarotene gel 0.1% in the treatment of verruca plana compared to imiquimod or 5-fluorouracil

NCT ID: NCT05291845 Recruiting - Clinical trials for Human Papilloma Virus

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Start date: April 3, 2022
Phase: Phase 2
Study type: Interventional

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

NCT ID: NCT05087849 Recruiting - Clinical trials for Human Papilloma Virus

Intralesional HPV Vaccine for Condylomata

Start date: April 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will investigate whether injecting genital warts with small quantities of the Gardasil 9 vaccine has an effect on the warts.

NCT ID: NCT04947332 Recruiting - Viral Wart Clinical Trials

Auto-inoculation of a Wart in Multiple Viral Warts

Start date: February 8, 2021
Phase: N/A
Study type: Interventional

This study is being conducted to see effectiveness of auto-inoculation of a wart in multiple viral warts. Patients with recurrent, multiple warts of all types, are being recruited for the study. A wart is excised, minced and then inoculated in a subcutaneous pocket made on the volar aspect of forearm. Patients are to be reviewed after every 4 weeks to note any reduction in number warts.

NCT ID: NCT04814446 Recruiting - Clinical trials for Palmar or Plantar Warts

Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts

VAC-WARTS
Start date: June 29, 2022
Phase: Phase 3
Study type: Interventional

Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV. For the palms and soles, HPV 2 has been the most frequently found but HPV 1, 4, 27, and 57 have also been described. Our hypothesis is that vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts patients of more than 15 years and 3 months of age.

NCT ID: NCT04620785 Recruiting - Verruca Vulgaris Clinical Trials

Photodynamic Therapy in Treatment of Verrucae

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

To assess the efficacy (clinically and dermoscopically) and safety of photodynamic therapy using intralesional injection of 4% methylene blue solution as a photosensitizer with IPL versus IPL only in treatment of warts.

NCT ID: NCT03977753 Recruiting - Plantar Wart Clinical Trials

Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts

EVAsION
Start date: February 17, 2020
Phase: Phase 4
Study type: Interventional

Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age. Conventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms. No specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus. The 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts. The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.

NCT ID: NCT03948321 Recruiting - Genital Warts Clinical Trials

Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts

Start date: May 10, 2019
Phase: N/A
Study type: Interventional

This study is being done to compare a new, continuous illumination and short Incubation time regimen of aminolevulinic acid photodynamic therapy(ALA-PDT) to a conventional regimen for treatment of small genital warts. The hypothesis is that the continuous illumination approach will be less or even no painful, but equally efficacious, as the old regimen.

NCT ID: NCT03901690 Recruiting - Clinical trials for Genital Wart Virus Infection

Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study

BETAGENWART
Start date: August 27, 2019
Phase: Phase 3
Study type: Interventional

In order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with Betaglucin 0.2% and 51 with Imiquimod 5%.